PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Cancer Research and Treatment10.4143/crt.2022.8832023552643-651Real-World Study Evaluating Safety and Effectiveness of Axitinib in Korean Patients with Renal Cell Carcinoma after Failure of One Prior Systemic TherapySang Joon Shin, Jae Lyun Lee, Tae Gyun Kwon, Byoung Young Shim, Ho Seok Chung, Sang-Hee Kim, Se Hoon Parkhttp://e-crt.org/upload/pdf/crt-2022-883.pdf, http://e-crt.org/journal/view.php?doi=10.4143/crt.2022.883, http://e-crt.org/upload/pdf/crt-2022-883.pdf
OncoTargets and Therapy10.2147/ott.s232732012111Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatmentViktor Grünwald, Merseburgerhttps://www.dovepress.com/getfile.php?fileID=13011
The Lancet Oncology10.1016/s1470-2045(14)70484-x2015164367-368NICE guidance on axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatmentNwamaka Umeweni, Boglarka Mikudina, Frances Sutcliffe, Andrew Stevenshttps://api.elsevier.com/content/article/PII:S147020451470484X?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S147020451470484X?httpAccept=text/plain
Value in Health10.1016/j.jval.2017.08.2422017209A440The Comparative Cost-Effectiveness of Cabozantinib, Everolimus and Axitinib in Advanced Renal Cell Carcinoma (ARCC) After Failure of Prior Therapy: Scottish PerspectiveJ Lister, A Vataire, B Amzal, J Dinet, J Meng, H Karcher, S Gabrielhttps://api.elsevier.com/content/article/PII:S1098301517305764?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1098301517305764?httpAccept=text/plain
European Urology Supplements10.1016/s1569-9056(19)31333-82019181e1841Real world evidence in renal cell carcinoma: A national, prospective, non-interventional study of nivolumab in patients with advanced renal cell carcinoma after prior therapy (NORA)M-O. Grimm, V. Grünwald, H. Müller-Huesmann, M. Schostak, W. Schultze-Seemann, J. Bedkehttps://api.elsevier.com/content/article/PII:S1569905619313338?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1569905619313338?httpAccept=text/plain
Value in Health10.1016/j.jval.2019.04.188201922S67PCN64 COST-EFFECTIVENESS OF CABOZANTINIB FOR PATIENTS WITH ADVANCED RENAL CELL CARCINOMA AFTER FAILURE OF PRIOR THERAPY IN BRAZILP. Serafini, S. Stefani, A. Nebel de Mellohttps://api.elsevier.com/content/article/PII:S1098301519303808?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1098301519303808?httpAccept=text/plain
Value in Health10.1016/j.jval.2018.09.227201821S39PCN144 - COST-EFFECTIVENESS OF CABOZANTINIB FOR PATIENTS WITH ADVANCED RENAL CELL CARCINOMA AFTER FAILURE OF PRIOR THERAPY IN SOUTH KOREAS. Kim, S. Han, H. Kim, H.S. Suhhttps://api.elsevier.com/content/article/PII:S1098301518335277?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1098301518335277?httpAccept=text/plain
ClinicoEconomics and Outcomes Research10.2147/ceor.s1598332018Volume 10243-250Cost-effectiveness comparison of cabozantinib with everolimus, axitinib, and nivolumab in the treatment of advanced renal cell carcinoma following the failure of prior therapy in EnglandJie Meng, Johanna Lister, Anne-Lise Vataire, Roman Casciano, Jerome Dinethttps://www.dovepress.com/getfile.php?fileID=41676, https://www.dovepress.com/getfile.php?fileID=41676
Value in Health10.1016/j.jval.2017.08.2452017209A441Cost-Effectiveness in England of Cabozantinib for Patients with Advanced Renal Cell Carcinoma (ARCC) After Failure of Prior TherapyJ Lister, A Vataire, B Amzal, J Dinet, J Meng, H Karcher, S Gabrielhttps://api.elsevier.com/content/article/PII:S109830151730579X?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S109830151730579X?httpAccept=text/plain
Clinical Genitourinary Cancer10.1016/j.clgc.2016.06.0192017151122-128Assessment of Efficacy, Safety, and Quality of Life of 124 Patients Treated With Axitinib as Second-Line Therapy for Metastatic Renal-Cell Carcinoma: Experience in Real-World Clinical Practice in JapanHideaki Miyake, Ken-ichi Harada, Seiichiro Ozono, Masato Fujisawahttps://api.elsevier.com/content/article/PII:S155876731630180X?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S155876731630180X?httpAccept=text/plain